In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
复制标题
DOI：
10.1016/j.micpath.2020.104228
复制
发表时间：
2020-08-01
影响因子：
3.8
通讯作者：
Raoult, Didier
中科院分区：
文献类型：
--
作者：
Andreani, Julien;Le Bideau, Marion;Raoult, Didier
人类冠状病毒SARS-CoV-2于2019年底出现，并导致高发病率和高死亡率的大流行。由于目前还没有针对这种病毒的有效药物，药物再利用代表着一种以低成本治疗数百万感染患者的短期策略。羟氯喹在体外具有抗病毒作用。在体内，它显示了疗效，特别是在初步临床试验中与阿奇霉素联合使用时。在这里，我们证明了羟氯喹和阿奇霉素在体外对SARS-CoV-2具有协同作用，其浓度与在人肺中获得的浓度相容。
Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.